Champions Oncology reported record annual revenue of $59.4 million and posted its first quarterly Adjusted EBITDA profit of $158,000, matching the consensus EPS of $‑0.05. The turnaround highlights growing margins and cash generation, offering investors a potential upside as the stock trades near $6.10.

Key Highlights

  • Annual revenue rose to $59.4 million, the highest in company history.
  • Fourth‑quarter oncology services margin expanded to 51%, up from 41% a year earlier.
  • Adjusted EBITDA turned positive in the quarter at $158,000 after a $1.2 million loss the prior year.
  • Cash on hand stood at $4.9 million with no debt recorded.

Champions Oncology (NASDAQ: CSBR) announced a fresh fiscal year topped by a $59.4 million revenue record and the first quarterly Adjusted EBITDA profit in its history, amounting to $158,000. The company posted earnings per share of $‑0.05, exactly matching analyst expectations. Revenue growth stemmed from a 12% rise in fourth‑quarter sales to $13.8 million, while margins improved sharply, underscoring a shift toward profitability that could reshape investor sentiment.

Revenue Surge Drives Momentum

The fiscal year concluded with total oncology revenue of $59.4 million, a 4% increase over the previous period, despite the absence of a $4.5 million data‑license windfall that had boosted last year’s top line. Quarter‑over‑quarter, sales climbed to $13.8 million from $12.4 million, reflecting stronger demand for the firm’s research services. Cost of oncology revenue fell to $6.8 million, a $462,000 (6%) reduction, helping lift the services margin to 51% from 41% a year earlier.

This margin expansion signals that the company’s cost‑control measures are beginning to translate into higher profitability, a critical factor for investors evaluating long‑term earnings potential.

Cost Discipline Fuels EBITDA Turnaround

Adjusted EBITDA shifted from a $1.2 million loss in the comparable quarter to a modest $158,000 gain, driven by tighter cost structures and strategic outsourcing reductions. Operating expenses stayed near $14.4 million, while the loss from operations narrowed to $522,000, inclusive of $357,000 in stock‑based compensation and $322,000 of depreciation and amortization. The company’s cash position settled at $4.9 million, with no debt on the balance sheet, positioning it to fund further growth without liquidity strain.

These financial improvements suggest a pathway to sustained positive cash flow, an essential criterion for value‑oriented shareholders. The market capitalization of $84 million sits within a 52‑week range of $5.50 to $8.74, indicating upside potential if the company continues delivering margin expansion. Short interest is modest at 1% of shares outstanding, representing 7.9 days of average volume to cover, suggesting limited bearish pressure.

The combination of a record top line, improving margins, and a positive cash balance provides a compelling case for investors seeking exposure to oncology research services at a relatively attractive valuation.

Upcoming Catalysts and Outlook

The company will release its detailed Form 10‑K filing on July 29, offering deeper insight into the drivers behind the revenue record and EBITDA reversal. The next earnings call scheduled for early August will allow management to discuss progress on radiopharmaceutical integration and data platform investments. These events will give investors clearer visibility into whether the margin improvements can be sustained and whether the firm can scale its commercial operations, setting the stage for future earnings growth.

Peers Moving on This News

  • Lifecore Biomedical Inc (LFCR) up 3.0%
  • Codexis Inc (CDXS) down 3.6%

Analysis based on the Form 8-K filed 27 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.